tradingkey.logo

Fulgent Genetics Inc

FLGT
查看詳細走勢圖
23.440USD
-0.270-1.14%
收盤 02/06, 16:00美東報價延遲15分鐘
723.22M總市值
虧損本益比TTM

Fulgent Genetics Inc

23.440
-0.270-1.14%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.14%

5天

-10.53%

1月

-15.96%

6月

+15.13%

今年開始到現在

-10.77%

1年

+45.23%

查看詳細走勢圖

TradingKey Fulgent Genetics Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Fulgent Genetics Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療服務供應商行業排名36/75位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為33.67。中期看,股價處於下降通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Fulgent Genetics Inc評分

相關信息

行業排名
36 / 75
全市場排名
181 / 4521
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Fulgent Genetics Inc亮點

亮點風險
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

分析師目標

基於 3 分析師
買入
評級
33.667
目標均價
+43.63%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Fulgent Genetics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Fulgent Genetics Inc簡介

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
公司代碼FLGT
公司Fulgent Genetics Inc
CEOHsieh (Ming)
網址https://www.fulgentgenetics.com/
KeyAI